Consensus guideline for the management of peritoneal mesothelioma.

Consensus Guideline for the Management of Peritoneal Mesothelioma.

Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors.

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study.

Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.

Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial.

Leveraging the pleural space for anticancer therapies in pleural mesothelioma.

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.

Response letter to "Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients".

Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.

Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.

Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.

Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).